Table 4.
Observed events at 5 years | Aspirin (assuming 42% RRI) | ||||
---|---|---|---|---|---|
Number | Incidence (%) | Incidence (%) | ARI (%) | NNH | |
Overall | 23 | 0.67 | 0.95 | 0.28 | 355 |
By CAC Score | |||||
CAC=0 | 9 | 0.42 | 0.60 | 0.18 | 567 |
CAC 1–99 | 12 | 1.43 | 2.03 | 0.60 | 167 |
CAC≥100 | 2 | 0.46 | 0.65 | 0.19 | 518 |
CAC≥400 | 0 | 0.00 | –* | –* | –* |
By ASCVD Risk | |||||
ASCVD Risk <5% | 5 | 0.30 | 0.43 | 0.13 | 794 |
ASCVD Risk 5–20% | 16 | 1.04 | 1.48 | 0.44 | 229 |
ASCVD Risk >20% | 2 | 0.93 | 1.32 | 0.39 | 256 |
Could not be computed.
Results presented as number or %. Follow-up was censored at 5 years. The 10-year ASCVD risk was estimated using the Pooled Cohort Equations.
Abbreviations: ARI = Absolute Risk Increase; ASCVD = atherosclerotic cardiovascular disease events; CAC = coronary artery calcium; NNH = number needed to harm; RRI = relative risk increase